Precision diagnosis of lupus nephritis: opportunities and role of biomarkers
Journal Title: Нирки - Year 2019, Vol 8, Issue 2
Abstract
The most common complication in patients with systemic lupus erythematosus is lupus nephritis (LN), a condition that can lead to end-stage kidney disease. In recent years, many serum and urine biomarkers, genetic studies have been proposed for the diagnosis of LN, but none of them entered into guidelines for clinical use. The majority of studies have been single-center with significant variability in cohorts, assays, and sample storage, leading to inconclusive results. It has become clear that no single biomarker is likely to be sufficient to diagnose LN, identify flares, and define the response to therapy and prognosis. A more likely scenario for future diagnostics is a panel of biomarkers for urine, serum, kidney tissue, and genetic biomarkers. The review summarizes the data on traditional and new serum, urinary and genetic biomarkers, discusses the feasibility of their use in clinical practice and the possibility of implementation for a more accurate diagnosis of LN. Each “panel” of biomarkers will provide a unique understanding of the various clinical issues of disease development and progression. Thus, the genetic panel can determine the likelihood of nephritis in a patient with systemic lupus erythematosus and which inflammatory pathways will be involved in the LN development. A urine biomarker panel can help distinguish between inflammation and fibrosis, eliminating the need for repeated biopsies. A serum biomarker panel can identify nephritogenic autoantibodies that increase the number of exacerbations, cause their severity and worsen the response to treatment. A more systematic and focused approach to the study of biomarkers will allow precision diagnosis to become a reality for patients with LN.
Authors and Affiliations
I. Yu. Golovach, Ye. D. Yehudina
Keywords
Related Articles
- EP ID EP570395
- DOI 10.22141/2307-1257.8.2.2019.166666
- Views 105
- Downloads 0
The use of diuretics in heart failure with congestion — a position statement from the Heart Failure Association of the European Society of Cardiology
The vast majority of acute heart failure episodes are characterized by increasing symptoms and signs of congestion with volume overload. The goal of therapy in those patients is the relief of congestion through achieving...
Immunobiological drugs in the treatment of rheumatic diseases
Rheumatic diseases (RD) are among the most common chronic diseases of the musculoskeletal system and connective tissue which are found in both adults and children. The cause of these pathological conditions can be change...
Cystatin C and chronic kidney disease in children
Background. Determination of diagnostically significant values of serum concentration of cystatin C in combination with the estimated glomerular filtration rate (GFR) gives clinicians an advantage in clearly differentiat...
Hypomagnesemia in Chronic Kidney Disease: Problem or Individual Characteristics of Certain Patients?
The article considers the problem of magnesium deficiency in patients with chronic kidney disease. It requires special attention from clinicians due to the increased risk of cardiovascular complications. The study reveal...
ALPHA-ERYTHROPOIETIN IN THE TREATMENT AND PREVENTION OF ANEMIA IN PATIENTS WITH CHRONIC KIDNEY DISEASE
The paper discusses current international recommendations on the diagnosis and treatment of anaemia in chronic kidney disease. Presents a detailed analysis of the alpha-erythropoietin, discussed the advantages and disadv...